TriangleHEALTH PROFESSIONAL · SOURCE READING
Zanubrutinib versus BR
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Evidence (zanubrutinib vs. BR):
A prospective randomized trial included 590 previously untreated patients aged 65 years or older. Patients were randomly assigned to receive zanubrutinib or BR.[16]
Source links and citations
A prospective randomized trial included 590 previously untreated patients aged 65 years or older. Patients were randomly assigned to receive zanubrutinib or BR.[16]
With a median follow-up of 26.2 months, the 2-year PFS rate was 85.5% (95% CI, 80.1%–89.6%) for patients who received zanubrutinib and 69.5% (95% CI, 62.4%–75.5%) for patients who received BR (HR, 0.42; 95% CI, 0.28–0.63; P < .0001).[16][Level of evidence B1]
Source links and citations
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice